Special Issue

Roles of the Tumor Microenvironment on Liquid Biopsy

Message from the Guest Editor

Cancer metastasis is the major cause of patient mortality and remains a daunting problem, both biologically and clinically. Although many advances have been made deciphering cancer in the circulation, mechanistic understandings, and precise underpinnings of crosstalk between circulatory tumor and normal cells, setting the stage for metastasis remains unknown. Historically, the enumeration of EpCAM-positive circulating tumor cells (CTCs) has allowed clinicians to estimate the overall metastatic burden in cancer patients, acting as an independent prognostic indicator of overall/progression-free survival of metastatic patients ("Liquid Biopsy"). However, thorough understanding of CTCs, CTC biomarkers and pathways, and CTC interactions with the tumor microenvironment, either in blood, bone marrow, or at organ sites is necessary for early detection and evaluation of treatment responses.

Guest Editor

Prof. Dr. Dario Marchetti

- Division of Molecular Medicine, Department of Internal Medicine, The University of New Mexico Health Sciences Center, Albuquerque, NM 87120, USA
- 2. Department of Pathology, The University of New Mexico Health Sciences Center, Albuquerque, NM 87120, USA
- 3. UNM Comprehensive Cancer Center, Albuquerque, NM 87131, USA

Deadline for manuscript submissions

closed (31 December 2021)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/54281

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

